Poudre de berbérine jaune vif et copeaux de racine d’épine-vinette sur une pierre sombre (image générée)

Berberine: same dose, different effect in women and men (2026 study)

Health & Nutrition Cyril Certain
Summarize or share this article:

A man and a woman take exactly the same berberine capsule, at the same dose, for three months. Logically, they should achieve the same result. A study published in October 2026 shows the opposite: in women, the decrease in cholesterol was almost three times stronger, and testosterone moved in the opposite direction depending on the sex.

I devoted a video to this study. This article follows its reasoning with the figures, the limitations, and the state of the file in Europe, where berberine is subject to a provisional unfavorable opinion. I am the founder of DIX, and our Fat Burner contains berberine: we therefore have an interest in this subject, and each figure below has its source.

The short answer

The result: at 1 g per day for 12 weeks, berberine lowered apoB, total cholesterol, LDL, and Lp(a) in women, with an effect almost three times weaker in men. Testosterone decreased in women and slightly increased in men: it is not a booster. In Europe, the EFSA estimates in a provisional opinion of 2026 that no dose of berberine can be considered safe; the final decision has not been made.

Cyril’s video: the Hong Kong study, its two lines of explanation, its limitations, and the European opinion.

Berberine in a nutshell

Berberine is a yellow molecule found in several plants, including barberry (Berberis vulgaris), and has long been used in traditional Chinese medicine. In the United States and the United Kingdom, it is freely sold as a supplement. On social media, it is nicknamed “the natural Ozempic.” However, no trial has directly compared it to this medication: the nickname stems from marketing, not science.

Two identical berberine capsules, one lit in blue, the other in pink, next to a barberry root (generated image)
Same capsule, two responses: that’s the whole subject of the study. Generated illustration image.

What is better established is its effect on blood lipids. Several trials and meta-analyses support this, and according to the study authors, the 2019 European recommendations on dyslipidemias cite it among the options for people who poorly tolerate statins. [1] [2] One question remained that no one had really asked: does it act the same way in women and men?

The study: two trials conducted in Hong Kong

A team from the University of Hong Kong conducted two randomized, double-blind, placebo-controlled trials. The first involved 84 men and was completed at the end of 2020. The second, years later, involved 100 women. All were between 20 and 65 years old and had slightly elevated cholesterol or triglycerides. For 12 weeks, half took 500 mg of berberine twice a day, the other half an identical capsule without berberine. [1]

The interesting detail: the men’s blood had been frozen at −80 °C. The researchers took it out to analyze it exactly like the women’s, with the same technique and in the same laboratory. This is what makes the comparison possible. The main criterion was apolipoprotein B (apoB). The trials were funded by a public fund from Hong Kong, and the authors declare no conflicts of interest.

Cholesterol: an effect almost three times stronger in women

In women, the results are clear. Compared to the placebo, apoB decreased by 0.13 g/L, from a baseline value of 0.9 g/L: about 14% less. Total cholesterol, LDL, triglycerides, and lipoprotein(a) also decreased, and these effects remain significant after correction for multiple comparisons. [1]

In men, the direction is the same, but the effect is much smaller: almost three times weaker on apoB, and nothing significant on LDL or Lp(a). The gender gap is significant on apoB, total cholesterol, LDL, and Lp(a), with heterogeneity from 83 to 85%.

💊
Same capsule, two responses Choose a marker: the height of the bars shows the strength of the effect of berberine against placebo, after 12 weeks. Effect size (standard deviations) 100 women and 84 men, 500 mg of berberine twice a day for 12 weeks, against placebo. Effects in standard deviations: the higher the bar, the stronger the effect. WomenMen ApoBTotal cholesterolLDLTriglyceridesLp(a)Testosterone ApoB, the main criterion: almost 3 times stronger effect in women Total cholesterol: 2.6 times more effect in women LDL: clear in women, not significant in men Triglycerides: decreased in both sexes Lp(a): decreased in women only Testosterone: same capsule, opposite direction In women, −0.13 g/L for a starting value of 0.9 g/L, about 14% less than under placebo. ApoB counts the particles of "bad" cholesterol. Significant decrease in both groups, much more marked in women. In men, the confidence interval ranges from −0.74 to +0.11: no conclusion can be drawn about an effect. This is the only marker where the gender gap is small. Since weight was not measured, a decrease in appetite could play a role. In men, +0.03: no effect. Lp(a) mainly depends on genes, which makes the decrease in women interesting. Decrease in women, just significant increase in men, with an increase in SHBG. It is not a testosterone booster. in womenin mennot significant Source: Zhao et al., JACC Asia, 2026, DOI 10.1016/j.jacasi.2026.06.011.

The results are expressed in standard deviations, a unit that allows different measurements to be compared with each other. Click on “Testosterone” in the chart: it’s the strangest part of the study.

Why apoB instead of LDL?

Each particle of “bad” cholesterol, LDL, IDL, or VLDL, carries a single apoB. Measuring it is like counting the trucks rather than weighing the goods. It is these particles that are directly involved in artery diseases, hence the growing interest of cardiologists in this marker.

The surprise of Lp(a)

Lipoprotein(a) is a cholesterol mainly determined by your genes, which diet and exercise have little effect on. The kind of guest who settles on your couch and never leaves. Seeing it decrease in women is therefore an interesting signal. With a caveat: most participants already had normal Lp(a) levels (medians around 18 to 20 mg/dL), and we don’t know what berberine would do for someone with very high levels.

Testosterone: the same capsule, the opposite effect

The researchers also looked at hormones. After 12 weeks, berberine lowered total testosterone in women (−0.42 standard deviation) and increased it in men (+0.43). [1] Same product, opposite effect.

In women, this is not necessarily bad news. In polycystic ovary syndrome, where testosterone is often too high, this is even what we seek to achieve, and this is where the only two previous trials in women had been conducted.

No, this is not a testosterone booster

In men, the increase is modest and barely significant: the lower bound of the confidence interval is at 0.004. It crosses the finish line, but in a decline. Moreover, berberine has also raised SHBG, the protein that holds testosterone in the blood. Free testosterone, the one that acts, has probably not changed.

Why the same dose does not have the same effect

The authors propose two avenues, without deciding.

What really happens in the blood. Another study, published in 2025, measured berberine after a single intake: in women, there was about 2.8 times more in total in the blood, with a peak 3.6 times higher. [3] A liver enzyme that breaks it down, CYP2D6, might not work the same way depending on the sex. At the same dose, women would therefore retain much more. It’s a bit like ordering the same coffee as your partner and seeing her receive, without extra charge, a gourmet coffee.

🩸
At the same dose, women retain more Berberine measured in the blood after the same single intake, with men as the reference. Compared to men (×) Pharmacokinetic study published in 2025, cited by the authors of the Hong Kong trial. A single intake, not three months of supplementation. MenWomen Total quantityBlood peak About 2.8 times more total berberine in women's blood A peak 3.6 times higher in women referencecompared to men A lead, not proof: in the Hong Kong trial, no one measured berberine in the blood. The liver enzyme CYP2D6 could explain it. Source: Blocher et al., Clinical Pharmacology & Therapeutics, 2025.

The hormones. Berberine activates AMPK, a kind of energy switch for cells, which fasting and physical activity also stimulate. Estrogens activate this same switch. In women, the two effects could add up. The authors themselves write that this mechanism remains to be verified, and in this study, no one measured berberine in the blood.

The limits of the study

Before rushing to buy, let’s look at what these two trials do not say.

Five limits to keep in mind

The authors describe them themselves. None invalidate the result, all invite confirmation.

1
Not at the same time
Men tested until 2020, women years later
2
Not made for comparison
Two separate trials, brought together after the fact
3
Markers
12 weeks of blood tests, no heart attacks counted
4
Weight not measured
Less appetite or direct effect? Doubt remains for triglycerides
5
8 stops out of 50
Against 2 under placebo, mostly for digestive disorders
  1. Men and women were not tested at the same time. The authors compare each berberine group to its own placebo, which limits bias, without eliminating it.
  2. The trials were not designed to compare sexes. The difference is clear, but it needs to be confirmed by a trial that includes both from the start.
  3. Twelve weeks, blood markers. Cholesterol was measured, not heart attacks. No one knows yet if this translates to fewer cardiovascular diseases.
  4. Neither weight nor waist circumference was measured. Twenty women reported digestive disorders under berberine, compared to eight under placebo. Does the lipid decrease come from a reduced appetite or direct action? For Lp(a), less sensitive to weight, the question is less relevant; for triglycerides, doubt remains.
  5. More dropouts under berberine. Among women, 8 out of 50 stopped in the berberine group compared to 2 out of 50 under placebo, mostly due to side effects, especially digestive. The main analysis only keeps those who completed it; redone with a more cautious method, it reaches the same conclusions, with slightly weaker effects.

Let’s add that all participants were of Chinese origin. On the safety side, no serious effects were reported over these three months, and liver enzymes (ALT and AST) remained stable. Keep in mind that berberine is not suitable for everyone: your stomach may let you know very quickly.

What Europe thinks of berberine

While Hong Kong tests berberine against cholesterol, Europe is closely examining it. On January 29, 2026, the EFSA, the European Food Safety Authority, adopted a draft opinion on plant preparations containing berberine, at the request of the French agency, Anses. [4] [5]

His conclusion: no dose can be considered safe. The EFSA relies in particular on genotoxicity signals observed in the laboratory, on data in rodents, on rare liver damage that cannot be predicted, and on missing studies.

Berberine in Europe: where is the case?

The steps known as of November 10, 2026, and what may follow.

  1. 2019
    An option mentioned in cardiologyAccording to the study authors, European cholesterol guidelines cite it for people who poorly tolerate statins.
  2. 2022
    France requests an evaluationAnses refers the matter to EFSA regarding the safety of berberine plants (EFSA-Q-2022-00803 dossier).
  3. Jan 29, 2026
    Draft opinion: no dose deemed safeSignals on DNA in the lab, data in rodents, rare unpredictable liver damage, missing studies.
  4. March 2 to May 4, 2026
    Public consultationManufacturers, researchers, and authorities can provide data.
  5. Oct. 2026
    The Hong Kong study is publishedIt focuses on efficacy, not on the rare effects that concern EFSA.
  6. Nov 10, 2026
    PendingNeither final opinion nor decision from the European Commission. Berberine remains authorized as a supplement.
  7. Next
    Three possible outcomesStatus quo, monitoring with a deadline to provide studies, or prohibition.

Sources: EFSA, draft opinion of January 29, 2026; NutraIngredients, March and July 2026; regulation (EC) 1925/2006, article 8.

A nuance matters: “we cannot set a safe dose” does not mean “it is dangerous”: it means that we do not have enough data to assert that it is safe.

A three-month trial on 100 people may show the absence of frequent severe effects. It cannot detect a rare reaction that would affect one person in several thousand. It is precisely this type of reaction that concerns the EFSA.

Before taking it

If you have cholesterol or are undergoing treatment, talk to your doctor: berberine does not replace any medication and may interact with some of them, as it inhibits liver enzymes that eliminate many (CYP2D6, CYP3A4). It should be avoided during pregnancy and breastfeeding; pregnant or breastfeeding women were actually excluded from the study.

And our Fat Burner?

Our Fat Burner contains 350 mg of berberine extract for 4 capsules, alongside nine other active ingredients: L-carnitine, L-tyrosine, ginger, mate, guarana, green tea, coleus, grapefruit, and cayenne pepper, plus a bit of black pepper. Each dose is indicated in milligrams on the label.

This is a much lower dose than the gram of pure berberine given daily in the study. So we won’t tell you it lowers your cholesterol: no such claims are allowed, and the study didn’t test it. We keep berberine because it remains a relevant molecule, with more and more studies, and we closely follow the EFSA’s opinion. If the regulations change, our formula will change with it.

Fat burner

10-in-1 Fat Burner: Ultra-complete formula combining L-Carnitine (1g), Berberine, and Forskolin to optimize fat…

39,90 €

In stock

What we retain

  1. Berberine does lower cholesterol in trials, and this study suggests it works better in women. It is a serious lead, which remains to be confirmed.
  2. It is neither a testosterone booster nor a replacement for your treatment.
  3. In Europe, its future is not written. The doses or recommendations may change, and berberine may no longer be authorized as a simple supplement. As of today, it is.

Ultimately, the most interesting lesson goes beyond berberine: the same dose does not mean the same effect. Before this study, there were only two trials on berberine in women, both in polycystic ovaries. A result obtained in men does not always copy-paste to women, and the vast majority of studies are still conducted on men.

Berberine: do you have the right benchmarks?

1 / 5

Your questions about berberine

Does berberine lower cholesterol?

In trials, yes. In the Hong Kong study published in 2026, 1 g per day for 12 weeks reduced apoB by about 14% in women compared to placebo, with an effect nearly three times weaker in men. It does not replace treatment: talk to your doctor about it.

Does berberine increase testosterone?

In the men of the study, total testosterone slightly increased, just significantly, but SHBG also increased: free testosterone probably did not change. In women, it decreased. This is not a testosterone booster.

Why does berberine act more in women?

Two hypotheses: women may retain more in the blood (2.8 times more in a 2025 study), and estrogens activate the same enzyme as berberine, AMPK. Neither has been verified in this study.

Is berberine banned in Europe?

No, not on November 10, 2026. EFSA published a provisional opinion in January 2026 stating that no dose can be considered safe. The final decision has not been made; it could range from monitoring to prohibition.

What are the side effects of berberine?

Mainly digestive issues: in the trial among women, 20 reported digestive disorders under berberine compared to 8 under placebo. No serious effects were observed over 12 weeks. It may interact with medications and is not recommended during pregnancy and breastfeeding.

To go further on berberine

To go further, this article covers the weight side.

Sources and studies cited

  1. Zhao JV, Chen B, Chan YH et al. Sex-Specific Lipid, Apolipoprotein B, and Lipoprotein(a) Responses to Berberine Based on 2 Randomized Placebo-Controlled Trials. JACC: Asia, 2026;6(10):2204-2216. Trials NCT06782646 (women) and NCT03770325 (men).
  2. Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 2020, cited by Zhao et al.
  3. Blocher JA et al. Sex-dependent effects of CYP2D6 on the pharmacokinetics of berberine in humans. Clinical Pharmacology & Therapeutics, 2025;117:250-260, cited by Zhao et al.
  4. EFSA. Draft opinion on the safety of plant preparations containing berberine (EFSA-Q-2022-00803), adopted on January 29, 2026, public consultation from March 2 to May 4, 2026.
  5. NutraIngredients. No safe intake level for berberine: EFSA opens consultation, March 10, 2026, and Safety in question: what is the future of berberine?, July 31, 2026.

Article from the video by Cyril Certain, supplemented by the full reading of the study. This content is informative and does not replace the advice of a healthcare professional.